Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CCND1 | P24385 | 19/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 19/20 | 1.00 |
| ▸ | CDK4 | P11802 | 4/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 3/20 | 1.00 |
| ▸ | CDK9 | P50750 | 3/20 | 1.00 |
| ▸ | CCND3 | P30281 | 3/20 | 0.82 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.79 |
| ▸ | RB1 | P06400 | 1/20 | 0.79 |
| ▸ | CDK1 | P06493 | 1/20 | 0.79 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25316105 | 1.00 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19863641 | 1.00 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26472010 | 1.00 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30550124 | 1.00 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30550413 | 1.00 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30550155 | 0.94 | CCNE1 (0.89) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30550306 | 0.94 | CCNE1 (0.89) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30550104 | 0.94 | CCNE1 (0.89) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30550274 | 0.93 | CCNE1 (0.87) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857405 | 0.92 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| WO-2021249258-A1 | DEUTERATED PYRIDOPYRIMIDINONES AND THEIR USE AS HIGHLY SELECTIVE CYCLIN-DEPENDENT KINASE 2 INHIBITORS | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2021-12-16 | — | — | WO | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | CDK2, CDK4, CCNI | CCNE1 47/4885CDK2 1/4885CCND1 27/4885 |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 28/4885CDK2 1/4885CCND1 39/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.